Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review

  1. Zijun Wang
  2. Siya Zhao
  3. Yuyi Tang
  4. Zhili Wang
  5. Qianling Shi
  6. Xiangyang Dang
  7. Lidan Gan
  8. Shuai Peng
  9. Weiguo Li
  10. Qi Zhou
  11. Qinyuan Li
  12. Joy James Mafiana
  13. Rafael González Cortés
  14. Zhengxiu Luo
  15. Enmei Liu
  16. Yaolong Chen
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Introduction

The purpose of this systematic review is to evaluate the efficacy and safety of using potential drugs: remdesivir and glucocorticoid in treating children and adolescents with COVID-19 and intravenous immunoglobulin (IVIG) in treating MIS-C.

Methods

We searched seven databases, three preprint platform, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> , and Google from December 1, 2019, to August 5, 2021, to collect evidence of remdesivir, glucocorticoid, and IVIG which were used in children and adolescents with COVID-19 or MIS-C.

Results

A total of six cohort studies and one case series study were included in this systematic review. In terms of remdesivir, the meta-analysis of single-arm cohort studies have shown that, after the treatment, 37.1% (95%CI, 0.0% to 74.5%) experienced adverse events, 5.9% (95%CI, 1.5% to 10.2%) died, 37.2% (95%CI, 0% to 76.0%) needed extracorporeal membrane oxygenation or invasive mechanical ventilation. As for glucocorticoids, the results of the meta-analysis showed that the fixed-effect summary odds ratio for the association with mortality was 2.79 (95%CI, 0.13 to 60.87), and the mechanical ventilation rate was 3.12 (95%CI, 0.80 to 12.08) for glucocorticoids compared with the control group. In terms of IVIG, the two included cohort studies showed that for MIS-C patients with more severe clinical symptoms, IVIG combined with methylprednisolone could achieve better clinical efficacy than IVIG alone.

Conclusions

Overall, the current evidence in the included studies is insignificant and of low quality. It is recommended to conduct high-quality randomized controlled trials of remdesivir, glucocorticoids, and IVIG in children and adolescents with COVID-19 or MIS-C to provide substantial evidence for the development of guidelines.

Related articles

Related articles are currently not available for this article.